Haresh Selvaskandan

Higher Specialist Nephrology Trainee | @KRUK Research Fellow (IgAN) | @GlomCon GN Fellow | python_student() | I heart glomeruli - we must save them all.

[Dr Roisin Thomas @RoisinThomas]

🚨 Exciting PhD Opportunity! 🚨
Join our cutting-edge research at the University of Leicester exploring mediators of loin pain in IgA nephropathy! #IgAN @IgAN_J @haresh11
https://t.co/aiiazbNtFL @IgAN_JBarratt

[Haresh Selvaskandan @haresh11]

@sonia_rgzr @poyanmehr @Alexgr23 @GrahamAbra @JeanHouMD @BetterCallSeeth 😂 this is accurate.

[Chloe @ChloeECWil]

Massive thank you to @uniofleicester, @IgAN_JBarratt, @haresh11, Lydia and Max for all the support. Sharing knowledge and learning from the experts

[Renal SpR Club @RenalSpRClub]

Come join us in Brighton for the autumn SpR club meeting on 14-15th October…book on before it’s too late ! https://t.co/0RyUxlMAZA

[Renal SpR Club @RenalSpRClub]

We are excited to announce that the next SpR club Autumn meeting is in sunny (hopefully) Brighton. We will have some of the biggest names in research attending, a great opportunity for networking. Also fish and chips by the seaside is nice. https://t.co/0RyUxlMAZA

[Haresh Selvaskandan @haresh11]

@Heather92200446 Congrats Heather!

[Rahul Ganatra @rbganatra]

1/
A patient receiving his first-ever dose of IV Iron (ferumoxytol) suddenly develops diffuse face & trunk flushing, chest pain, myalgias, and anxiety.

Blood pressure is normal and lungs are clear.

You are called to the bedside to assess.

How likely is anaphylaxis?

[Dr Hannah Young @hmlyoungphysio]

Out today! The @KidneyBeamTrial protocol and baseline paper. A novel digital health intervention to support physical activity and self-management for ppl with CKD. Watch this space for the results- huge potential to impact care @sharleneuk @Kidney_Research https://t.co/6sHdKuQSlw

[GlomCon @GlomCon]

Pneumocystis Jirovecii Pneumonia Prophylaxis by Dr. Dilushi Wijayaratne, MBBS MD (Medicine) MRCP(UK)

Check it out here 👉🏻 https://t.co/vuCPCQef4n

#GlomCon

[World Kidney Day @worldkidneyday]

An estimated 850 million people worldwide suffer from chronic kidney disease, and it is expected to become the fifth leading cause of death globally by 2040. Read more about the burden of CKD worldwide here: https://t.co/IvKZgjqhg6
#WorldKidneDay #KidneyDisease #GlobalIssue

[Radcliffe Cardiology @radcliffeCARDIO]

🔴Don't miss this broadcast next week, where @ShelleyZieroth @BonanadClara @AndrewFrankel1 & @drjamesburton explore emerging data and the changing landscape of medical management of hyperkalaemia https://t.co/DeurRzYgfc

#CardioTwitter #MedEd

[Sketchplanations @sketchplanator]

Whenever you look to generalise from a small sample watch out for sampling bias (and all other sorts of bias that can easily creep in).

Extreme example from How to Lie with Statistics by Darrell Huff: https://t.co/NY6MU54FhO

[Dr. Louise Oni @louise_oni]

Come work with me !

[Renal SpR Club @RenalSpRClub]

Not to be missed crash course for those embarking on a career as renal registrar

[Dr Anant Pilawan MD DM 🇮🇳 CMC Vellore @Glomkeeper]

Sparsentan in patients with IgA nephropathy - treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Published today. @TheLancet

[Haresh Selvaskandan @haresh11]

#ISNWCN conference buddies!

[Renal SpR Club @RenalSpRClub]

#nephworking #renalsprclub #dinnertime @CaesarOlGeezer @GlomerulaRajah @Javeria_Xx @nimmikins @alannaturtles @haresh11

[ASN Kidney News @KidneyNews]

The temptation to use immunosuppression in crescentic IgAN is strong, but is it appropriate? Check out a case study: https://t.co/5kDm8vJNSs

#IgANephropathy

[Arkana Laboratories @arkanalabs]

This #eyeSCANDy image is an acellular scanning EM from a biopsy with membranous glomerulonephritis, stage I showing numerous small shallow depressions representing the site of immune complexes which were extracted corresponding to “pinholes” viewed on silver stain. #pathart

[The UK Kidney Association @UKKidney]

📣 Guideline for review 📣

Draft UKKA guideline on Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with #KidneyDisease is now available for review & comments:

https://t.co/OwYifDfuBJ

#SGLT2 #CKD @AndrewFrankel1 @willkidney @drjamesburton